Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Immunization of mice with inactivated polio vaccine (IPV) with concurrent dosing of poliovirus antiviral V-073 showed no detrimental impact on the elicitation of serum-neutralizing antibodies. A strategy involving coadministration of antiviral V-073 and IPV can be considered for the management of poliovirus incidents.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147355 | PMC |
| http://dx.doi.org/10.1128/CVI.05147-11 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pocapavir treatment of enterovirus encephalitis in a patient with X-linked Agammaglobulinemia.
Clin Immunol
August 2025
Unit of Pediatric Immunology, Pediatrics Clinic, University of Brescia; Department of Clinical and Experimental Sciences University of Brescia, ASST Spedali Civili Brescia, Italy; European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN-RITA), Utrech
We report the case of a young boy with X-linked agammaglobulinemia (XLA) who developed progressive gait instability and postural difficulties. Initial cerebrospinal fluid (CSF) analyses and viral PCR testing were negative; however, a brain biopsy confirmed chronic enteroviral encephalitis. The patient was treated with two compassionate-use cycles of pocapavir, in combination with ongoing high-dose intravenous immunoglobulin (IVIG) therapy.
View Article and Find Full Text PDFSocial interactions shape antiviral resistance outcomes in poliovirus via eco-evolutionary feedback.
bioRxiv
May 2025
Department of Genome Sciences, University of Washington, Seattle, WA 98103.
Antiviral resistance evolution poses a major obstacle for controlling viral infections. A promising strategy is to target shared viral proteins that allow drug susceptible viruses to sensitize resistant ones during cellular coinfection, muting selection for resistance. Pocapavir, a poliovirus capsid inhibitor, employs this sociovirological strategy.
View Article and Find Full Text PDFDevelopment and validation of a sensitive method to quantify a poorly ionized drug, pocapavir, in C57BL/6 mouse plasma.
Bioanalysis
March 2025
Drug Metabolism, Gilead Sciences Inc., Foster City, CA, USA.
Background: Pocapavir is an antiviral agent that has shown in vitro potency against poliovirus. It necessitates investigation into its efficacy and safety profiles. Therefore, the development of a sensitive and reliable bioanalytical method to quantify pocapavir drug levels and characterize its pharmacokinetic (PK) profiles is imperative.
View Article and Find Full Text PDFEmerging Therapeutics in the Fight Against EV-D68: A Review of Current Strategies.
Influenza Other Respir Viruses
December 2024
Infection and Immunity Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia.
Enterovirus-D68 (EV-D68) was first identified in 1962 in pediatric patients with acute respiratory conditions in California, USA (US). From the 1970s to 2005, EV-D68 was underestimated due to limited data and serotyping methods. In 2014, the United States experienced outbreaks of acute flaccid myelitis (AFM) in children EV-D68 positive.
View Article and Find Full Text PDFUpdate on nonpolio enterovirus and parechovirus infections in neonates and young infants.
Curr Opin Pediatr
June 2023
Department of Pediatrics, Section of Infectious Diseases.
Purpose Of Review: To review the epidemiology, clinical manifestations, and treatment strategies of nonpolio enterovirus and parechovirus (PeV) infections, and identify research gaps.
Recent Findings: There is currently no approved antiviral agent for enterovirus or PeV infections, although pocapavir may be provided on a compassionate basis. Elucidation of the structure and functional features of enterovirus and PeV may lead to novel therapeutic strategies, including vaccine development.